Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

1. Evaluation and Management of Testosterone Deficiency

Evaluation and Management of Testosterone Deficiency 1 Executive Summary Testosterone testing and prescriptions have nearly tripled in recent years; however, it is clear from clinical practice that there are many men using testosterone without a clear indication. 1-3 Some studies estimate that up to 25% of men who receive testosterone therapy do not have their testosterone tested prior to initiation of treatment. 2, 3 Of men who are treated with testosterone, nearly half do not have (...) their testosterone levels checked after therapy commences. 2, 3 While up to a third of men who are placed on testosterone therapy do not meet the criteria to be diagnosed as testosterone deficient, 2, 3 there are a large percentage of men in need of testosterone therapy who fail to receive it due to clinician concerns, mainly surrounding prostate cancer development and cardiovascular events, although current evidence fails to definitively support these concerns. Given the clinical and commercial testosterone

2018 American Urological Association

2. Testosterone Replacement Guidelines

Testosterone Replacement Guidelines Page | 1 BSPED Guideline: Testosterone Therapy in Infancy and Adolescence Initial authors: R El-Khairi, N Shaw, EC Crowne (November 2016) Revision: A Chinoy, EC Crowne, M Skae (January 2018) Scope This guideline is intended for general paediatricians and paediatric endocrinologists who are regularly managing boys with absent/delayed puberty requiring exogenous testosterone therapy. This includes boys with hypogonadotrophic hypogonadism (HH) of various (...) aetiology, androgen deficiency secondary to testicular failure (hypergonadotrophic hypogonadism) of various aetiology, and constitutional delay of growth and puberty (CDGP). The aim of testosterone replacement therapy is to mimic the normal pattern of puberty and mimic requirements at different stages of pubertal development 1 . This guideline aims to provide the clinician with testosterone dosing regimens for pubertal induction, progression and post-pubertal maintenance, as well as for penile growth

2019 British Society for Paediatric Endocrinology and Diabetes

3. Testosterone (Testavan) - testosterone replacement therapy for adult male hypogonadism

Testosterone (Testavan) - testosterone replacement therapy for adult male hypogonadism Published 08 April 2019 1 www.scottishmedicines.org.uk Product update SMC2152 testosterone 20mg/g transdermal gel (Testavan®) Ferring Pharmaceuticals Ltd 8 March 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following (...) an abbreviated submission testosterone gel (Testavan ® ) is accepted for restricted use within NHSScotland. Indication under review: testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. SMC restriction: patients requiring a transdermal delivery system. Testosterone (Testavan ® ) is bioequivalent to another testosterone transdermal preparation and costs less. Advice context: No part of this advice may be used

2019 Scottish Medicines Consortium

4. Testosterone replacement in menopause

Testosterone replacement in menopause BRITISH MENOPAUSE SOCIETY T ool for clinicians Information for GPs and other health professionals 1 of 4 1 How much and where does it come from? Testosterone is an important female hormone. Healthy young women produce approximately 100 – 400 mcg per day. This represents three to four times the amount of estrogen produced by the ovaries. Approximately half of endogenous testosterone and precursors are derived from the ovaries e.g. androstenedione and half (...) from the adrenal glands e.g. dehydroepiandrosterone. Some of the effects are direct and some due to peripheral conversion to estrogen by aromatase. Testosterone levels naturally decline throughout a woman’s lifespan. Loss of testosterone is particularly profound after iatrogenic i.e. surgical and medical menopause and premature ovarian insufficiency when testosterone production decreases by more than 50%. 2 What is its role in women? Testosterone contributes to libido, sexual arousal and orgasm

2019 British Menopause Society

5. Testosterone Testing - Protocol

Testosterone Testing - Protocol Testosterone Testing - Protocol - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend theme_data_collection data_frontend Data theme_5_collection theme_5_frontend theme_5_collection theme_5_frontend Driving & Transportation (...) & Culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes & Tax Credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration Search default_collection default_frontend Section Navigation Testosterone Testing - Protocol Effective Date: September 19, 2018 Recommendations and Topics Scope This protocol reviews the appropriate use of serum testosterone testing in men and women aged ≥ 19 years. This document is intended to direct

2019 Clinical Practice Guidelines and Protocols in British Columbia

6. Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study. Full Text available with Trip Pro

Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study. We assessed the risk of ischemic stroke, transient ischemic attack, and myocardial infarction associated with testosterone replacement therapy (TRT) among aging men with low testosterone levels.Using the UK Clinical Practice Research Datalink (CPRD), we formed a cohort of men aged 45years or older with low testosterone levels and no evidence (...) 1.11-1.27) per 100 persons per year). Compared with nonuse, current use of TRT was associated with an increased risk of the composite outcome (HR 1.21; 95% CI 1.00-1.46). This risk was highest in the first six months to two years of continuous TRT use (HR 1.35; 95% CI 1.01-1.79), as well as among men aged 45-59years (HR 1.44; 95% CI 1.07-1.92).TRT may increase the risk of cardiovascular events in aging men with low testosterone levels, particularly in the first 2years of use. In the absence

2019 American Journal of Medicine

7. Testosterone Treatment in Adult Men with Age-Related Low Testosterone Full Text available with Trip Pro

Testosterone Treatment in Adult Men with Age-Related Low Testosterone Testosterone Treatment in Adult Men With Age-Related Low Testosterone | Annals of Internal Medicine | American College of Physicians '); } '); })(); Sign in below to access your subscription for full content INDIVIDUAL SIGN IN | You will be directed to acponline.org to register and create your Annals account INSTITUTIONAL SIGN IN | | Subscribe to Annals of Internal Medicine . You will be directed to acponline.org to complete (...) your purchase. Search Clinical Guidelines | 21 January 2020 Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians Free Amir Qaseem, MD, PhD, MHA; Carrie A. Horwitch, MD, MPH; Sandeep Vijan, MD, MS; Itziar Etxeandia-Ikobaltzeta, PhD; Devan Kansagara, MD, MCR; for the Clinical Guidelines Committee of the American College of Physicians Amir Qaseem, MD, PhD, MHA American College of Physicians, Philadelphia, Pennsylvania (A.Q

2020 American College of Physicians

8. Beyond tribulus (Tribulus terrestris L.): The effects of phytotherapics on testosterone, sperm and prostate parameters. (Abstract)

Beyond tribulus (Tribulus terrestris L.): The effects of phytotherapics on testosterone, sperm and prostate parameters. Phytotherapeutic approaches have been widely proposed to improve male health. Despite the well-touted effects of tribulus (Tribulus terrestris L) on men's health, an optimal phytotherapy remains an elusive challenge.We sought to critically analyze the evidence in the phytotherapic literature beyond the effects of tribulus on testosterone (T) concentration and sperm analysis

2019 Journal of Ethnopharmacology

9. Medicalization of aging and the testosterone deficiency syndrome

Medicalization of aging and the testosterone deficiency syndrome Servicio Navarro de Salud / Osasunbidea Plaza de la Paz, s/n - 31002 Pamplona T 848429047 - F 848429010 farmacia.atprimaria@cfnavarra.es Drug and Therapeutics Bulletin of Navarre. Spain abstract n Objective: to carry out a critical appraisal of the Testosterone Deficit Syndrome (TDS), also known as low testosterone or T-low, its diagnosis and management. Materials and methods: a bibliographic search was carried out in the TRIP (...) database and PubMed with the following key words: “testosterone deficiency”, “late-onset hypogonadism”, “male andropause” and “androgen deficiency in aging males” filtered by the type of study (clinical practice guidelines, systematic reviews, meta-analyses or clinical trials). Information on consumption and sales was obtained from invoiced prescriptions in Navarre from 2001 upto 2011. Results: many of the signs and symptoms that define this syndrome overlap with those produced by other health problems

2012 Drug and Therapeutics Bulletin of Navarre (Spain)

10. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline

Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline Guidelines CMAJ ©2015 8872147 Canada Inc. or its licensors CMAJ 1 CME T estosterone deficiency syndrome, also known as late-onset hypogonadism, is a clinical and biochemical syndrome that can occur in men in association with advancing age. The condition is characterized by deficient testicular production of testosterone. It may affect multiple organ systems and can result in substantial health (...) consequences. 1 The management of testosterone deficiency syndrome in men is associated with much contro- versy, creating confusion and reluctance among health practitioners in dealing with the subject. A small number of professional bodies 2,3 have pub- lished guidelines on the topic, yet a multidisci- plinary guideline with specific Can adian content did not exist. This is relevant because there are important differences in health care systems com- pared with other jurisdictions in North America

2015 CPG Infobase

12. Testosterone replacement therapy and cardiovascular risk. (Abstract)

Testosterone replacement therapy and cardiovascular risk. Testosterone is the main male sex hormone and is essential for the maintenance of male secondary sexual characteristics and fertility. Androgen deficiency in young men owing to organic disease of the hypothalamus, pituitary gland or testes has been treated with testosterone replacement for decades without reports of increased cardiovascular events. In the past decade, the number of testosterone prescriptions issued for middle-aged (...) or older men with either age-related or obesity-related decline in serum testosterone levels has increased exponentially even though these conditions are not approved indications for testosterone therapy. Some retrospective studies and randomized trials have suggested that testosterone replacement therapy increases the risk of cardiovascular disease, which has led the FDA to release a warning statement about the potential cardiovascular risks of testosterone replacement therapy. However, no trials

2019 Nature reviews. Cardiology

13. Testosterone Full Text available with Trip Pro

Testosterone Top results for testosterone - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for testosterone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

14. The effect of testosterone replacement therapy on prostate specific antigen (PSA) levels: a systematic review and meta-analysis

The effect of testosterone replacement therapy on prostate specific antigen (PSA) levels: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

15. Testosterone and Physical Function in HIV+ Men

Testosterone and Physical Function in HIV+ Men Testosterone and Physical Function in HIV+ Men - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Testosterone and Physical Function in HIV+ Men The safety (...) by (Responsible Party): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Study Details Study Description Go to Brief Summary: Men infected with the HIV virus (the virus that causes AIDS) often lose weight even though they may try to eat more food to gain weight. The reasons for this weight loss are not clear. Many men with HIV have low levels of testosterone in their blood. Testosterone is a hormone that is naturally produced in the bodies of both men and women and has important

2005 Clinical Trials

16. Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank. Full Text available with Trip Pro

Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank. To determine whether endogenous testosterone has a causal role in thromboembolism, heart failure, and myocardial infarction.Two sample mendelian randomisation study using genetic variants as instrumental variables, randomly allocated at conception, to infer causality as additional randomised evidence.Reduction by Dutasteride of Prostate (...) participants, 13 691 had thromboembolism (6208 men, 7483 women), 1688 had heart failure (1186, 502), and 12 882 had myocardial infarction (10 136, 2746). In men, endogenous testosterone genetically predicted by variants in the JMJD1C gene region was positively associated with thromboembolism (odds ratio per unit increase in log transformed testosterone (nmol/L) 2.09, 95% confidence interval 1.27 to 3.46) and heart failure (7.81, 2.56 to 23.8), but not myocardial infarction (1.17, 0.78 to 1.75

2019 BMJ

17. Sleep disturbance as a clinical sign for severe hypogonadism: efficacy of testosterone replacement therapy on sleep disturbance among hypogonadal men without obstructive sleep apnea. (Abstract)

Sleep disturbance as a clinical sign for severe hypogonadism: efficacy of testosterone replacement therapy on sleep disturbance among hypogonadal men without obstructive sleep apnea. The present subanalysis of the EARTH study investigates the effects of one year testosterone replacement therapy (TRT) on sleep disturbance among hypogonadal men without obstructive sleep apnea.Sleep disturbance was defined as three or more points in question 4 of the aging males symptoms (AMS) questionnaire. All

2018 The aging male : the official journal of the International Society for the Study of the Aging Male Controlled trial quality: uncertain

18. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting (...) registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) (TRAVERSE) The safety and scientific validity of this study is the responsibility

2018 Clinical Trials

19. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice. Full Text available with Trip Pro

Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice. To explore the practice and attitudes of uro-oncologists in the UK regarding monitoring testosterone levels and the use of testosterone replacement therapy (TRT) in their prostate cancer patients treated with androgen deprivation therapy (ADT).An expert-devised online questionnaire was completed by the members (...) of the British Uro-oncology Group (BUG).Of 160 uro-oncologists invited, 84 completed the questionnaire. Before initiating ADT in patients with non-metastatic prostate cancer, only 45% of respondents measured testosterone levels and 61% did not measure testosterone at all during ADT in the adjuvant or neoadjuvant setting. However, in men with metastatic prostate cancer, 71% of the uro-oncologists measured testosterone before starting ADT and the majority continued testing during treatment. Approximately two

2018 International journal of clinical practice

20. Relation of Testosterone Levels to Mortality in Men With Heart Failure. Full Text available with Trip Pro

Relation of Testosterone Levels to Mortality in Men With Heart Failure. We aimed to investigate the impact of testosterone on the prognosis of heart failure (HF), as well as the underlying cardiac function, cardiac damage, and exercise capacity. We analyzed consecutive 618 men with HF (age 65.9 years). These patients were divided into quartiles based on their serum levels of total testosterone (TT): first (TT > 631 ng/dl, n = 154), second (462 < TT ≤ 631 ng/dl, n = 155), third (300 < TT ≤ 462 (...) peptide and cardiac troponin I, among the 4 groups. Left ventricular ejection fraction and B-type natriuretic peptide did not differ among the groups. In contrast, the fourth quartile, compared with the first, second, and third groups, had higher levels of troponin I and lower peak VO2 (p <0.05, respectively). Decreased serum testosterone is associated with myocardial damage, lower exercise capacity, and higher mortality in men with HF.Copyright © 2018 The Author(s). Published by Elsevier Inc. All

2018 American Journal of Cardiology